Stay updated on Nivolumab and Cyclophosphamide for R/R AML Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page.

Latest updates to the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.6.6 appears on the page, replacing v3.6.5. This indicates a minor update to page metadata or formatting without altering the study details, eligibility criteria, or outcomes.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedRevision: v3.6.5 was added, and multiple Study Documents entries (Informed Consent Form, Study Protocol and SAP, and related items) were removed from the page.SummaryDifference18%

- Check41 days agoChange DetectedThe page revision label changed from v3.6.3 to v3.6.4, indicating a new edition of the page. This reflects a minor update to the document rather than a substantive modification to the study details.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision label on the page changed from v3.6.2 to v3.6.3. This reflects a minor update to the study record's documentation and does not change the study content or participant-facing information.SummaryDifference0.1%

- Check69 days agoChange DetectedThe page revision was updated from v3.6.0 to v3.6.2, reflecting a minor documentation update to the study page and its linked materials.SummaryDifference0.1%

- Check84 days agoChange DetectedThe page now includes new guidance and join sections (How to Read a Study Record, Common Questions, How to Join a Study) and indicates that recruitment is closed ('No longer looking for participants'). Additionally, the 'Intervention / Treatment' heading was removed and the older revision note ('Revision: v3.5.5') was dropped, reflecting an updated and streamlined study page.SummaryDifference0.4%

Stay in the know with updates to Nivolumab and Cyclophosphamide for R/R AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page.